Devax, Inc.
Devax, Inc., a medical device company focused on developing next generation products for interventional cardiology, today announced that the Company has completed patient enrollment in the DIVERGE clinical trial evaluating its novel AXXESS™ Bifurcation Stent System. The DIVERGE trial, a prospective, multi-center trial which enrolled 302 patients, is the largest study conducted to date with a drug-eluting stent specifically designed for treating bifurcation lesions.
Contact Details
Executives
Chairman
Michael R. (Mike) Henson
President, CEO, and Director
Jeffrey H. (Jeff) Thiel